Interfering with these S100A10 interactions could be envisioned for the treatment of the corresponding diseases, including depression [114], although a beneficial effect of an upregulation of S100A10 expression, e.g., through 1,25-dihydroxyvitamin D3 [109], still needs to be demonstrated. The gene discussed is S100A10; the disease is depressive disorder.